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Abstract
In fulminant hepatic failure (FHF), the devel-
opment of hepatic encephalopathy is associ-
ated with grossly abnormal concentrations
of plasma amino acids (PAA). Normalization
of the ratio of branched-chain amino acids to
aromatic amino acids (Fischer’s ratio) corre-
lates with clinical improvement. This study
evaluated changes in PAA metabolism dur-
ing 4 h of isolated, normothermic extracor-
poreal liver perfusion using a newly de-
signed system containing human blood and
a rhesus monkey liver. Bile and urea produc-
tion were within the physiological range. Re-
lease of the transaminases AST, ALT and
LDH were minimal. The ratio of branched
(valine, leucine, isoleucine) to aromatic (tyro-
sine, phenylalanine) amino acids increased
significantly. These results indicate that a xe-
nogeneic extracorporeal liver perfusion sys-
tem is capable of significantly increasing
Fischer’s ratio and may play a role in treating
and bridging patients in FHF in the future.
Introduction
Fulminant hepatic failure (FHF) is regular-
ly associated with encephalopathy [1]. If sup-
portive measures fail, then the stage of en-
cephalopathy progresses and brain edema de-
velops [2]. For many patients, liver transplan-
tation is the therapy of choice that yields the
best prognosis for survival and quality of life
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[3–5]. Transplantation must be carried out
before irreversible neurologic complications
secondary to brain edema occur. Apart from
liver transplantation, therapeutic measures
such as continuous hemofiltration and plasma
exchange have not been very successful in pre-
venting FHF patients from developing brain
edema to date [6].
During FHF, grossly abnormal concentra-
tions of a wide variety of plasma amino acids
(PAA) can be measured. PAA play a decisive
role in the pathophysiology of hepatic enceph-
alopathy (HE) and brain edema [7–9]. In-
creasing the ratio of branched-chain amino
acids (BCAA) to aromatic amino acids (AAA)
correlates well with an improvement in HE
[10]. Under clinical conditions the source of
PAA is difficult to determine. The source can
be either the diseased liver or the body muscle
mass.
During the late 60s and early 70s, extracor-
poreal liver perfusion with livers from differ-
ent species was investigated as a method to
treat patients in FHF, expecting the affected
liver would regenerate [11, 12]. Recently, the
same technical approach of liver perfusion
has been applied in FHF patients waiting for
liver transplantation [13]. So far, no evidence
has been presented that a normothermic ex-
tracorporeal liver perfusion (NELP) system
is capable of improving the BCAA to AAA
ratio.
This study examines the role of an im-
proved NELP system utilized under defined
conditions on changes in PAA levels and the
BCAA/AAA ratio.
Methods
Six rhesus monkeys (Macaca mulatta) of either sex
weighing 10.3 B 0.6 kg were used as multiple organ
donors. All animals received a standard commercial
diet and were allowed free access to food and water
prior to hepatectomy.
Organ Harvesting. After intramuscular premedica-
tion with ketamine hydrochloride, anesthesia was in-
duced with etomidate and azaperone followed by endo-
tracheal intubation. Maintenance of anesthesia was car-
ried out with halothane, fentanyl and a mixture of oxy-
gen and nitrous oxide on a mechanical ventilator. A
midline abdominal incision was made from the xiphoid
process to pubis. The liver was dissected and the infra-
and suprahepatic vena cava, portal vein, common bile
duct, and hepatic artery were exposed. The common
bile duct was ligated and divided as distally as possible.
The gallbaldder was excised and the cystic duct ligated.
Branches of the celiac and hepatic arteries to the stom-
ach and duodenum were ligated and divided along with
the coronary artery and phrenic veins and all connective
tissue surrounding the liver. A ligature was placed
around the descending thoracic aorta. The kidneys and
ureters were manipulated before organ perfusion. A
thoracotomy was carried out, and the heart and lungs
were prepared for organ removal. For organ perfusion
one catheter was placed in the abdominal aorta and a
second catheter in the portal vein. The portal vein and
the abdominal aorta were perfused with 400 ml Univer-
sity of Wisconsin (UW) solution, respectively. For stor-
age, the liver was wrapped in a double plastic bag and
stored at 0°C in UW solution. The storage period var-
ied from 60 to 80 min.
Liver Perfusion. At the end of the storage period,
livers were prepared for perfusion by inserting spring
perfusion cannulae into the portal vein, vena cava and
hepatic artery. Then the liver was placed in a plastic
bag and immersed in water (37 °C) contained in a spe-
cially designed perfusion chamber. The liver was sub-
jected to intermittent oscillations produced by an ex-
ternal pump. The pressure difference was in the range
of 0 to 25 cm H2O. The liver was perfused via cannulae
in the portal vein and hepatic artery. The suprahepatic
vena cava was ligated while blood outflow was allowed
through the infrahepatic vena cava. According to phys-
iological conditions, the mean arterial pressure was
adjusted to 100 mm Hg and the portal venous pressure
to 15 cm H2O. The flow rates measured under these
conditions were about 150 ml/min through the hepatic
artery and 250 ml/min through the portal vein. Our
perfusion system allows for easy control and adjust-
ment of flow rates and perfusion pressures. The Dide-
co D701 pediatric hollow fiber oxygenator was sup-
plied with a mixture of 95% oxygen and 5% carbon
dioxide. Bile production was measured continuously.
Since the livers were stored in UW solution, we flushed
them with warm and equilibrated perfusate according
to our clinical protocol. The first 200 ml of perfusate
were discarded before perfusion was started.
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Fig. 1. The liver was placed in a
sterile plastic bag, which was then
immersed at 37°C in water and
was subjected to intermittent oscil-
lations produced by an external
pump. The liver was perfused via
cannulae in the portal vein and he-
patic artery. The suprahepatic vena
cava was ligated while blood out-
flow was allowed through the infra-
hepatic vena cava. The Dideco
D701 pediatric hollow-fiber oxy-
genator was supplied with a mix-
ture of 95% oxygen and 5% carbon
dioxide. The simultaneous dialysis
circuit consisted of two Stöckert
roller pumps, a Gambro ALWALL
GFS 12 fiber dialyzer and a reser-
voir containing 10 liters of dialy-
sate.
Perfusate. The perfusate consisted of 800 ml hu-
man blood and 400 ml of a balanced electrolyte solu-
tion to give a total volume of 1.2 liters. The blood was
donated by healthy blood donors 90 min before each
perfusion. The monkeys were tested not to have any
preformed antibodies for blood groups O and B. Only
blood from donors of blood groups O and B was used
as perfusate.
Dialysis. The dialysis circuit consisted of a Gambro
ALWALL GFS12 fiber dialyzer (Gambro, Lund, Swe-
den), two Stöckert roller pumps (Stöckert-Shiley, Mu-
nich, Germany) and a reservoir for the dialysate. The
perfusate was pumped at a steady rate of about 150 ml/
min through the dialyzer. The dialysate was pumped at
a rate of 1,000 ml/min from the reservoir and back in a
recirculating fashion. Both sides of the dialzyer were
controlled and if necessary adjusted to keep the volumes
of perfusate/dialysate constant. The perfusate which
had passed the dialyzer is pumped back into the main
perfusion circuit to be oxygenated. The perfusion-dialy-
sis apparatus including all tubes and the fiber oxygena-
tor were primed with an albumin-containing electrolyte
solution to avoid hemolysis. The priming solution was
discarded after 10 min of perfusion. Heparin was con-
tinuously injected at a rate of 2,500 U/h to protect the
perfusate in the circuit from clotting. Figure 1 shows a
diagram of the perfusion circuit.
Dialysate. Ten liters of dialysate were prepared
before each experiment. The dialysate consisted of
commercially available acid and basic bicarbonate
concentrate and distilled water. The dilution ratios
were 1:1.78 and 1:42.22, respectively. The prime buff-
er of the dialysate was sodium bicarbonate. The elec-
trolyte concentrations of the dialysate (in mmol/l) were
Na+ 141, K+ 2.9, Ca2+ 0.8, Mg2+ 0.38, Cl– 113,
CH3COO– 2.5 and HCO3– 37. The osmolality of the
dialysate was 296 mosm/kg.
Amino Acids. The samples were deproteinated by
adding 50 mg sulfosalicylic acid (Merck) per 1-ml sam-
ple, centrifugated at 10,500 g for 5 min, ultrafiltered
through a membrane with a pore size of 0.2 Ìm (Minis-
art NML, Sartorius), adjusted to a pH of 2.2, and finally
diluted 1:2 with diluent containing norleucine as an
internal standard prior to injection. Analyses were per-
formed on a Pharmacia/LKB Alpha Plus amino acid
analyzer containing ultrapack cation-exchange resin
column (Pharmacia, Uppsala, Sweden) and equipped
with a Shimadzu integrator. The post-column ninhy-
drin reaction was carried out at 135°C. The system
used changes in the eluent lithium citrate buffer from
pH 2.8/0.2 mol/l to pH 3.55/1.65 mol/l and a regenera-
tion solution of 0.3 mol/l lithium hydroxide. Changes
in column temperature were between 32 and 75°C.
Analyses. Six livers were perfused. Perfusate and
dialysate samples were taken before, during (at 15 and
30 min) and after perfusion (every 30 min). Perfusion
was carried out over a period of 4 h. Enzyme activities
are given in units per liter per 100 g liver weight. Elec-
trolyte concentrations are given in millimoles per liter.
Amino acid levels are expressed as means B SEM (in
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Fig. 2. The activities of AST, ALT,
and LDH (U/l/100 g) increased af-
ter reperfusion until 15 min. This
was atrributed to hepatocellular
damage caused by preservation
injury. During the following
225 min, the enzyme activity re-
mained fairly constant. Based on
the significant increase in urea
(mmol/l) in both perfusate (1.2 li-
ters of circulating volume) and di-
alysate (10 liters of circulating vol-
ume) and a normal production of
bile, the system apparently pro-
vided physiological conditions for
the perfused livers.
Ìmol of amino acid per liter of sample). Comparison
between the BCAA/AAA ratios was done by Student’s
t test. A p value !0.05 was considered statistically sig-
nificant.
Results
All livers regained a pink and homogenous
appearance within 10 min of starting perfu-
sion. There was no macroscopic evidence of
inadequate perfusion. As observed from on-
line monitoring, the vascular resistance was
highest at the start of perfusion, but settled
then down to a steady state after about 20 min.
No technical failures or interruptions occurred
during the perfusion of these 6 livers.
Electrolytes, Enzymes, Urea and Bile
Production
The concentration of potassium, sodium
and calcium in the perfusate varied within
physiological limits. The dialysate neutralized
excess electrolyte released after reperfusion.
As it has been shown recently [14], the dialysis
unit assists in maintaining physiological con-
centrations of pH and electrolytes throughout
the perfusion period.
During the whole perfusion process, no en-
zyme activity could be detected in the dialy-
sate. Figure 2 shows the changes in enzyme
activity in the perfusate and urea concentra-
tions in perfusate and dialysate during the 4 h
of liver perfusion. The activity of AST in the
perfusate before reperfusion was 8 U/l/100 g.
Following 15 min of perfusion it increased to
25 U/l/100 g. After 240 min of perfusion the
activity measured was 27 U/l/100 g. ALT in-
creased from 11 U/l/100 g before reperfusion
to 21 U/l/100 g 15 min thereafter. The activi-
ty of ALT for the remaining 225 min of perfu-
sion was 17–23 U/l/100 g and without a clear
trend in either direction. LDH activity in-
creased from 123 U/l/100 g before reperfusion
to 155 U/l/100 g after 240 min. Similar to
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Fig. 3. The BCAA (valine, leucine, and isoleucine) and
the AAA concentrations (tyrosine and phenylalanine)
are given during 4 h of liver perfusion. PAA concentra-
tions (Ìmol/l) of the perfusate (closed symbols) and
dialysate (open symbols) are given. The point –15 cor-
responds to initial levels in the perfusate and dialysate.
Time point 0 min reflects the concentrations of PAA
after an equilibration period of 15 min between the
perfusate (1.2 liters) and the dialysate (10 liters) just
prior to liver reperfusion. Positive time points corre-
spond to the period of liver perfusion. Means B SEM.
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AST and ALT, the largest increase in LDH
release was measured immediately after re-
perfusion.
During the equilibration period, the con-
centration of urea in the perfusate was 2.8
mmol/l. The concentration of urea at the end
of perfusion was 6.9 mmol/l in the perfusate.
The amount of urea in the dialysate paralleled
the increase in the perfusate. After equilibri-
um, but before reperfusion, the urea concen-
tration was 1.1 mmol/l. It increased steadily
reaching 4.5 mmol/l at 240 min. Bile produc-
tion was noted about 20 min after reperfu-
sion. The average amount of bile produced
per 100 g liver weight was 2.6 ml during the
1st h of perfusion, 3.5 ml during the 2nd h,
3.3 ml during the 3rd h and 2.5 ml during the
4th h of perfusion.
A more detailed description of perfusion
parameters has been given recently [15].
Amino Acids
The concentrations of amino acids in the
perfusate and dialysate are given in figures 3
and 4. Time point –15 min corresponds to the
PAA concentration of the perfusate just be-
fore starting dialysis. At time point 0 min the
perfusate had been dialysed for 15 min, but
reperfusion of the liver had not begun.
The ratios of BCAA/AAA [(valine+leu-
cine+isoleucine)/(tyrosine+phenylalanine)] in
the perfusate are given in figure 5. At –15 (be-
fore dialysis), 0, 60 and 240 min, the ratios
were 3.1, 3.8, 8.8, and 12.1, respectively, in
the perfusate. Calculation of the ratios for the
dialysate gave very similar results. At 0 min,
the ratio was 3.6, at 60 min the ratio was 8.7
and at 240 min it was 12.9. The increased
BCAA/AAA ratios between 0 (before liver
perfusion) to 60 and 240 min after liver reper-
fusion were statistically significant in both the
perfusate (p ! 0.01 and p ! 0.001) and dialy-
sate (p ! 0.01 and p ! 0.001).
Discussion
Approximately 2,000 cases of FHF are
diagnosed annually in the United States, with
mortality approaching 80% [16]. Despite im-
provements in conservative medical treat-
ments, liver transplantation remains the ther-
apy of choice for a large number of patients
[17].
In patients with FHF, PAA levels deviate
considerably [18]. The BCAA valine, leucine
and isoleucine are low – in contrast to most
other PAA [19]. There is strong clinical and
experimental evidence that elevated PAA lev-
els are a prerequisite for the development of
HE and brain edema [9, 10]. Normalization
of PAA has been previously attempted by
hemodialysis and plasma exchange [20]. In a
group of 26 patients with FHF and signs of
grade IV coma, levels of BCAA were lowest in
those patients that subsequently died [18].
The adjustment of the molar BCAA/AAA ra-
tio from 1 (e.g. in hepatic coma) towards 3
(normal subjects) has a beneficial effect upon
encephalopathy [19]. The BCAA/AAA ratio is
increased in patients receiving supplemental
BCAA [21]. The role of oral BCAA supple-
ments in the treatment of chronic HE is not
yet established, and conflicting opinions have
been advanced [22–26]. Two meta-analyses
of randomized clinical trials support the view
that BCAA are improving hepatic encepha-
lopathy even when given orally [27, 28]. Al-
though BCAA and AAA play important roles
in the development of brain edema, experi-
mental evidence is lacking that an extracor-
poreally perfused liver can improve this ratio.
Liver function in an NELP system is deter-
mined by appropriate physiological perfusion
conditions.
We have developed a perfusion system in
which the liver is immersed in a closed perfu-
sion chamber that allows for intermittent
pressure oscillations. This proved to be indis-
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Fig. 5. The ratios of valine+leu-
cine+isoleucine/ tyrosine+phenyl-
alanine concentrations were calcu-
lated on the basis of their perfusate
concentration (Ìmol/l) at 0, 60, and
240 min. In FHF, the ratio seen
clinically is close to 1. The ratio
increased from 3.8 before liver per-
fusion (i.e. 0 min) to 8.8 after
60 min and further increased to
12.1 after 240 min of perfusion.
Both increases were statistically
significant.
pensable for homogeneous peripheral perfu-
sion particularly in the portal venous system
[29]. Recently, we have shown that NELP can
be further improved by simultaneous dialysis
of the perfusate [14].
On the basis of physiological amounts of
bile produced (11.9 ml/100 g/4 h), very low
activities of AST, ALT, and LDH (fig. 2), and
the lack of gross or histologic evidence of
poorly perfused areas, it is our opinion that
this system provides excellent physiologic
perfusion conditions.
Since PAA metabolism depends on the
functional integrity of the liver, the results of a
Fig. 4. The concentrations of alanine, glutamate, glu-
tamine, glycine, histidine, lysine, serine, and threonine
in the perfusate and dialysate are shown. Perfusion
conditions and parameters were identical to those in
figure 3.
carefully perfused extracorporeal liver should
be similar to those found under clinical condi-
tions. We therefore analyzed changes in PAA
concentrations within the perfusate. The de-
sign of our perfusion system consists of two
closed circuits, one of 1.2 liters for the perfu-
sate and one of 10 liters for the dialysate. Due
to the circuit design of our perfusion, all con-
centrations of PAA within the perfusate de-
crease from the moment the dialyzer was con-
nected to the perfusion system. This is the
result of a dilution phenomenon since PAA
cross the membrane of the dialyzer. There-
fore, concentrations of PAA in the dialysate
were included in the calculation for uptake or
production of amino acids.
Once equilibration of the perfusion and
dialysis circuit was established, reperfusion of
the liver was started at time point 0 min. Fol-
lowing reperfusion, changes in PAA concen-
trations in the perfusate or dialysate could
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only be attributed to their release or utiliza-
tion by the liver.
The concentration of all BCAA – valine,
leucine and isoleucine – increased significant-
ly in the perfusate as well as in the dialysate
during the 4-hour perfusion. The AAA phe-
nylalanine increased slightly to plasma con-
centrations noted before perfusion while the
other AAA tyrosine decreased during perfu-
sion. As a result, the BCAA/AAA ratio in-
creased from 3.8 to 8.8 (p ! 0.01) after 60 min
and to 12.1 after 240 min of perfusion (p !
0.001). The increase from 3.8 (normal ratio)
towards artificially high ratios of 8.8 and 12.1
should provide a HE patient with some bene-
fit since the patient’s pathologically low ratio
of around 1 would increase substantially. This
view is further supported by a similarly in-
creased ratio in the 10 liters of dialysate.
Although perfusate concentrations of
threonine, alanine and tyrosine were initially
low, these dropped further during perfusion.
Serine was released after reperfusion and then
taken up by the liver, which may be due to a
gluconeogenic effect because the rate of glu-
cose synthesis from alanine and serine is far
higher than that observed for all other PAA
during liver perfusion [30]. While this might
not play an important role in the elevated
PAA levels during FHF, threonine, serine,
alanine and tyrosine are likely to be metabo-
lized in larger quantities if the extracorporeal
liver perfusion is performed as an isolated
perfusion over a longer period of time, i.e. for
preservation or pharmacological studies. We
would suggest to substitute for their loss either
by addition to the perfusate or to the dialy-
sate. This suggestion is further based on an
observation during normothermic liver perfu-
sion of ischemia-damaged livers in which ad-
dition of amino acids was of particular impor-
tance for liver resuscitation [31].
The concentration of glycine, histidine, ly-
sine, glutamine, and glutamate increased in
the perfusate as well as in the dialysate. We
cannot conclude with certainty that the extra-
corporeally perfused liver would release these
PAA when perfused with high concentrations
of PAA, e.g. in patients with FHF, but it
seems rather unlikely that it will metabolize
large quantities of these amino acids [32].
More than 600 enzymatic systems are
known currently causing many metabolic
changes in case of liver failure [33]. More like-
ly, HE is of a multifactorial origin. In this con-
text, the importance of the amino acid pattern
in the pathogenesis of HE becomes more and
more evident [26, 34].
For the first time we could show that an
improved NELP system significantly raises
the BCAA/AAA ratio. This system therefore
may improve the encephalopathic state of
FHF patients waiting for liver transplanta-
tion.
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